Oncology pharmacists are important to the oncology care team, as they can bring a unique perspective to treatment planning, according to Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC.
Approval Alert | Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.
Patients with locally advanced or metastatic urothelial cancer may now receive enfortumab vedotin plus pembrolizumab following its approval by the FDA.
Advertisement
Advertisement
Trending on CancerNetwork
1
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
2
Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease
3
FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma
4
Why is Radiotherapy Not More Accessible as a Cancer Treatment?
5
